Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

First patient dosed in a Phase 2 study with LiPlaCis in prostate cancer

Regulatory

Clinical update: Dovitinib DRP data mining successfully completed and new LiPlaCis data continues to support an FDA breakthrough designation strategy

Regulatory

Communique from EGM in Oncology Venture A/S

Regulatory

Oncology Venture receives positive feed-back from the FDA on approval pathway for LiPlaCis and DRP in the US

Regulatory

Oncology Ventures CEO Peter Buhl Jensen buys shares in the Company

Regulatory

Claus Frisenberg Pedersen, CCO in Oncology Venture buys shares in the Company

Regulatory

Claus Frisenberg Pedersen, CCO in Oncology Venture buys shares in the Company

Regulatory

Peter Buhl Jensen, CEO in Oncology Venture buys shares in the Company

Regulatory

Correction new weekday: Oncology Venture: Notice to Convene Extraordinary General Meeting

Regulatory

Oncology Venture: Notice to Convene Extraordinary General Meeting

Regulatory

Oncology Venture A/S: Publication of financial report Q3 2018

Regulatory

Oncology Venture enters into financing agreement

Non-Regulatory

OV – Update Regarding Participation at Investor Events in Q4 2018

Regulatory

OV – Clinical up-date

Regulatory

OV – OV increases its share capital due to warrant exercise

Non-Regulatory

OV – Oncology Venture requests meeting with FDA to discuss pathway for LiPlaCis and DRP approval in the US

Regulatory

OV – First prostate cancer patient included in Oncology Venture’s Phase 2 study of Irofulven for personalized treatment

Non-Regulatory

OV: Oncology Venture to Participate at Upcoming Investor Events in Q4 2018

Regulatory

OV – Oncology Venture receives authority clearance to expand an ongoing Phase 2 study of LiPlaCis by inclusion of prostate cancer patients

Non-Regulatory

OV – Oncology Venture’s PARP inhibitor Evaluation for Childhood Cancer Passes First Feasibility Steps